for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Travere Therapeutics Inc

TVTX.OQ

Latest Trade

20.46USD

Change

-3.04(-12.94%)

Volume

65,945

Today's Range

20.34

 - 

22.45

52 Week Range

14.50

 - 

33.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
23.50
Open
21.74
Volume
65,945
3M AVG Volume
11.63
Today's High
22.45
Today's Low
20.34
52 Week High
33.04
52 Week Low
14.50
Shares Out (MIL)
60.30
Market Cap (MIL)
1,450.46
Forward P/E
-13.40
Dividend (Yield %)
--

Next Event

Travere Therapeutics Inc Presenting at Bank of America Global Research Healthcare Conference (Virtual)

Latest Developments

More

Travere Therapeutics Reports First Quarter 2021 Financial Results

Travere Therapeutics Posts Q4 Loss Per Share Of $2.37

Travere Therapeutics Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Travere Therapeutics Inc

Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (ARB). It's pipeline also includes also include OT-58, an investigational human enzyme replacement therapy. OT-58 is being developed for the treatment of classical homocystinuria (HCU). The Company's commercial products include Chenodal, Cholbam, Thiola and Thiola EC.

Industry

Biotechnology & Drugs

Contact Info

3611 Valley Centre Dr, Suite 300

SAN DIEGO, CA

92130-3330

United States

+1.760.2608600

http://www.retrophin.com/

Executive Leadership

Gary A. Lyons

Independent Chairman of the Board

Eric M. Dube

President, Chief Executive Officer, Director

Laura M Clague

Chief Financial Officer, Senior Vice President

Elizabeth E. Reed

Senior Vice President, General Counsel and Corporate Secretary

William E Rote

Senior Vice President and Head of Research and Development

Key Stats

1.33 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.2K

2020

0.2K

2021(E)

0.2K
EPS (USD)

2018

-2.540

2019

-3.460

2020

-1.520

2021(E)

-1.721
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.31
Price To Book (MRQ)
5.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
101.95
LT Debt To Equity (MRQ)
101.95
Return on Investment (TTM)
-36.87
Return on Equity (TTM)
-31.15

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up